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Summary Endurance time on submaximal exercise tests is a sensitive measure in
detecting changes after medical intervention and is used as an outcome in clinical
trials, although there has been little discussion regarding the appropriate intensity.
Therefore, we investigated whether there were differences in exercise responses
between endurance tests at high versus moderate intensity, and analyzed which test
was more appropriate.
Thirty-seven patients with chronic obstructive pulmonary disease participated in
the study. They performed cycle endurance tests at high and moderate submaximal
workloads representing 80% and 60% of the maximum work rate reached on
progressive cycle ergometry, respectively. Each type of exercise test was performed
after inhaling salbutamol 400 mg, ipratropium bromide 80 mg or an identical placebo.
Endurance time on the 80% endurance test was much shorter than on the 60%
endurance test. The coefficients of variation for the endurance time were lower on
the 80% test. Statistically significant improvements in the endurance time after
bronchodilators in comparison to placebo were found only on the 80% test.
When using the endurance time as an outcome, the high intensity endurance test
is preferable to the moderate intensity endurance test, as the high intensity test
demonstrated shorter exercise time, less variability and higher sensitivity.
& 2004 Elsevier Ltd. All rights reserved.
Introduction
Exercise capacity has become an important clinical
outcome measure in patients with chronic obstruc-
tive pulmonary disease (COPD), in addition to
airflow limitation evaluated by forced expiratory
volume in 1 s (FEV1), because exercise capacity is
difficult to predict from resting pulmonary func-
tion1 and can be the most significant predictor of
mortality in COPD.2 Several methods for evaluating
exercise capacity have been developed, including a
6-min walking test, progressive exercise testing and
a submaximal endurance test, using a cycle
ergometer or treadmill.
Among some indices of exercise capacity, ex-
ercise endurance time has recently begun to be
used in clinical trials.3 It has been demonstrated to
be more sensitive in detecting the changes after
bronchodilator administration than either walking
distance or peak oxygen uptake ’VO2 in patients with
COPD.4 O’Donnell et al.5 similarly reported that the
endurance time was reliable, being both reprodu-
cible and responsive to changes in COPD. There-
fore, direct measurement of endurance time is
recommended in clinical trials to avoid under-
estimation of the true clinical benefits by relying
too heavily on changes in FEV1 to assess therapeutic
efficacy.6
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There are, however, no standard protocols for
sub-maximal endurance testing; the appropriate
intensity of exercise for endurance testing is a
subject for discussion. Therefore, in the present
study, we proposed to investigate whether there
would be any differences in exercise responses
between the two different exercise procedures at
high versus moderate intensity, and to analyze
which test would be more appropriate in clinical
trials.
Methods
Patients
We recruited 67 consecutive patients with clinically
stable COPD, as defined by the American Thoracic
Society (ATS),7 to investigate the effects of inhaled
b2-agonists (salbutamol) and anticholinergic agents
(ipratropium bromide) on exercise endurance be-
tween January 1999 and December 2001.8 Among
these patients, 37 agreed to participate in the
present additional study to compare exercise
responses during high versus moderate intensities
of endurance exercise. Entry criteria for the
present study were: (1) age over 50 years; (2) a
smoking history of more than 20 pack-years; (3)
FEV1 of less than 80% of the predicted value; and
(4) best post-bronchodilator FEV1/forced vital
capacity (FVC) of less than 0.7. Exclusion criteria
included: (1) an exacerbation of airflow limitation
within the last 3 months; (2) a history of asthma;
(3) other diseases likely to affect exercise; (4)
severe hypoxemia defined as an arterial oxygen
tension (PaO2) less than 8 kPa at rest; and (5)
treatment with oral bronchodilators, and oral or
inhaled corticosteroids over the preceding 4 weeks.
Written informed consent was obtained from all
patients before the study.
All subjects underwent baseline pulmonary func-
tion testing at least 12 h after the withdrawal of
bronchodilators. In accordance with the method
described by the ATS9, spirometric testing for
determining FEV1 and FVC was performed using a
spirometer (AUTOSPIRO AS-600, Minato Medical
Science Co. Ltd., Osaka, Japan) which was cali-
brated with a 3.0-l syringe. The largest FEV1 and
FVC values from three maneuvers were then
analyzed. The residual volume (RV) was measured
by the closed-circuit helium method, and the
carbon monoxide transfer coefficient (KCO) was
measured by the single-breath technique (CHES-
TAC-65V, Chest, Tokyo, Japan). Predicted values for
the pulmonary function indices were calculated
according to the recommendations of the Japan
Society of Chest Diseases10.
Exercise tests
The symptom-limited progressive exercise test was
performed on a calibrated, electrically braked
cycle ergometer (Corival WLP-400, Lode, Gronin-
gen, The Netherlands)4. Subjects breathed through
a low resistance unidirectional valve (Rudolph Face
Mask Exercise Testing, Hans Rudolph Inc., Kansas
City, USA) attached to their face mask. Exercise
data were recorded using an automated exercise
testing system (Desktop Diagnostics/CPX, Medical
Graphic Corporation, St. Paul, USA) which converts
the breath-by-breath analog input into a digital
form on-line. The minute ventilation ( ’VE) and
oxygen and carbon dioxide tension in the expired
air were determined every eight breaths, and the
mean ’VE; ’VO2 and carbon dioxide output
’VCO2 were
then calculated. The gas analyzer was calibrated
just before the study with air and a standard
reference gas mixture (15% oxygen, 5% carbon
dioxide). Patients began unloaded cycling for 3min,
after which the power output was increased
progressively by increments of 1W every 3 sec to
the limit of tolerance. The arterial oxygen satura-
tion SaO2 was measured continuously by pulse
oximetry (N-200 pulse oximeter, Nellcor Inc.,
Hayward, USA), and the heart rate (HR) by
electrocardiography (Life Scope 8, Nihon Koden
Co., Tokyo, Japan). During exercise, symptoms of
breathlessness were scored with the Borg scale (0–
10),11 which was presented on the board within
easy view of the patients. They rated their
perceived level of breathlessness by pressing an
electronic button whenever they felt a change in
the severity of their breathlessness. The maximum
work rate (Wmax) was defined as the highest work
level that was reached. Similarly, peak ’VO2 ; peak
’VCO2 and peak
’VE were the highest levels reached
during exercise.
Sub-maximal endurance tests were performed on
the cycle ergometer at 80% (high intensity) and 60%
(moderate intensity) of the Wmax reached on the
progressive cycle ergometry. After unloaded pedal-
ing for 3min, the power output was increased to
that work level. The patients continued cycling at
the constant workload until the test was stopped
according to the same criteria as used for progres-
sive cycle ergometry, and the endurance time was
then recorded. Borg scores during exercise were
also recorded as recorded for progressive cycle
ergometry.
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Study design
During the initial screening, the subjects practiced
progressive cycle ergometry on at least two occa-
sions, and were familiarized with rating breath-
lessness using the Borg score11 during exercise.
Exercise tests were performed around the same
time on seven separate days over a 2-week period.
Inhaled bronchodilators were not used for at least
12 h before starting each test day.
On day 1, symptom-limited progressive cycle
ergometry was performed, and then the individual
Wmax was determined as the highest work level
reached. This was performed at 60min after
inhaling 400 mg (4 puffs) of salbutamol plus 80 mg
(4 puffs) of ipratropium bromide using a metered-
dose inhaler (MDI) with a spacer device (InspirEa-
set, Schering-Plough K.K., Osaka, Japan)12. On at
least one occasion between days 1 and 2, subjects
practiced the cycle endurance test at a constant
work rate of 80% of the Wmax reached on day 1.
On days 2–4 and 5–7, the cycle endurance tests
were performed at 80% (80% test) and 60% (60%
test) of the Wmax on progressive cycle ergometry,
respectively. During each 3-day period, tests were
performed at 40min after inhaling 400 mg (4 puffs)
of salbutamol, 80 mg (4 puffs) of ipratropium
bromide or an identical placebo in a randomized,
double-blind, cross-over fashion. The spirometric
parameters were then assessed before and at 30
and 60min after inhalation. Prior to each spiro-
metric measurement, the pulse rate and blood
pressure were measured after at least 5min of rest.
Statistical analysis
Results are expressed as mean7SD, unless otherwise
stated. Comparisons of the values between the
different exercise tests and between placebo and
bronchodilators were performed by a two-tailed
paired-t-test (parametric data) or a Wilcoxon signed
rank test (nonparametric data). When comparing
the variability of the endurance time at different
exercise settings, the coefficient of variation was
calculated by expressing the standard deviation as a
percentage of the mean. Relationships between two
sets of data were analyzed by Spearman’s correla-
tion coefficient test. A P-value of less than 0.05 was
considered to be statistically significant.
Results
The baseline characteristics of the 37 COPD
patients enrolled in the study are presented in
Table 1. Their age averaged 70.875.7 years, and
their average FEV1 was 1.2470.44 l (47.5716.0%pre-
dicted). Mild to severe COPD patients were included
in the study. Two patients were dropped from the
study due to acute exacerbation of COPD and knee
pain, respectively, during the moderate intensity
(60%) exercise endurance tests, and 35 completed
the study.
Physiologic data on the endurance tests at 80%
and 60% of the Wmax are presented in Table 2. The
endurance time was much shorter at 80% of the
Wmax than at 60% (Po0:001). The coefficients of
variation were 53.8 (placebo), 57.6 (salbutamol)
and 50.5 (ipratropium bromide) in the 80% test, and
84.0, 76.6 and 84.6, respectively, in the 60% test. In
addition, salbutamol and ipratropium bromide
produced significant improvements by 22 s
(P ¼ 0:02) and 21 s (P ¼ 0:007) in comparison to
the placebo in the 80% test. However, these
improvements did not reach statistical significance
in the 60% test (P¼ 0.07 and 0.06, respectively).
Fig. 1 shows the difference in endurance time
between bronchodilators and placebo for each
exercise intensity.
The endurance time after placebo was strongly
correlated between the 80% and 60% exercise tests
(Spearman’s correlation coefficients [rs]¼ 0.71,
Po0:001). However, the change in the endurance
time between salbutamol and placebo in the 80%
test was not significantly correlated with the
change in the endurance time between salbutamol
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Table 1 Characteristics of the 37 patients with
COPD.
Mean7SD Range
Male/Female, n 36/1
Age (years) 70.875.7 58–80
Smoking (pack-years) 66736 26–195
FEV1 (l) 1.2470.44 0.51–1.93
FEV1 (%predicted) 47.5716.0 19.5–78.4
FVC (l) 2.6770.55 1.33–3.43
FVC (%predicted) 78.8714.5 47.6–101.4
FEV1/FVC (%) 46.0710.5 18.2–63.6
TLC (l) 5.8070.78 4.04–7.56
TLC (%predicted) 107.9713.9 74.2–134.4
RV/TLC (%) 48.878.7 33.8–71.0
TLCO (%predicted) 58.4718.3 21.7–102.6
KCO (mmol/min/l/kPa) 0.9970.34 0.30–1.76
Resting PaO2 (kPa) 9.971.0 8.2–12.7
Resting PaCO2 (kPa) 5.670.6 3.9–6.9
TLC¼ total lung capacity; RV¼residual volume;
TLCO¼ carbon monoxide transfer factor; KCO¼ carbon
monoxide transfer coefficient; PaO2¼ arterial oxygen
tension; PaCO2¼ arterial carbon dioxide tension.
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and placebo in the 60% test (rs ¼ 0:09; P ¼ 0:58).
This lack of correlation was similarly observed
between ipratropium bromide and placebo
(rs ¼ 0:03; P ¼ 0:87).
Peak ’VO2 ; peak
’VCO2 and peak
’VE tended to be
higher in the 80% test (Table 2). In contrast, the
peak Borg score was somewhat higher in the 60%
test. There were no significant differences in peak
heart rates and minimal SaO2 between 80% and 60%
tests, except for the peak heart rate after
ipratropium bromide.
Fig. 2 shows the Borg scores over time after
placebo during cycle endurance tests at 80% and
60% of the Wmax in patients with COPD. Dyspnoea
continued to increase from the start to the peak
level in the 80% test. However, in the 60% test, the
increase in dyspnoea was slow, especially after
6min.
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Table 2 Physiological data on the cycle endurance tests at 80% and 60% of the maximum work rate in patients
with COPD.
Drug 80% 60% P-valuen
Endurance time (s) Placebo 1957105 5367450 o0.001
SB 2177125w 5947455 o0.001
IB 2167109z 6057512 o0.001
Peak ’VO2 (ml/min) Placebo 8527274 8147247 0.03
SB 8737269 8487238z 0.39
IB 8907283z 8347224 0.009
Peak ’VO2 (ml/min) Placebo 9687370 8537257 o0.001
SB 10077350w 9097255y 0.003
IB 10267370z 8847240w o0.001
Peak ’VE (l/min) Placebo 42714 40711 0.12
SB 45714z 43712y 0.28
IB 45714z 42711z 0.02
Peak Borg score Placebo 6.571.3 7.071.3 0.007
SB 6.471.4 6.971.4 0.01
IB 6.671.4 7.071.3 0.02
Peak heart rate (beats/min) Placebo 117713 115717 0.39
SB 120716 121717w 0.55
IB 119715 116716 0.03
Minimal SaO2 (%) Placebo 9276 9277 0.87
SB 9275 9376 0.76
IB 9276 9276 0.83
Values are expressed as mean7SD. SB¼ salbutamol; IB¼ ipratropium bromide.
nP-Values obtained by comparisons between 80% and 60% endurance exercise testing.
wPo0:05; significant differences from the placebo.
zPo0:01:
yPo0:001:
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Figure 1 Difference in the endurance time between
salbutamol and placebo (circle), and between ipratro-
pium bromide and placebo (square) in the cycle
endurance tests at 80% (open) and 60% (closed) of the
maximum work rate in patients with COPD. (Values are
shown as mean72SD.)
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Discussion
We demonstrated that the endurance time in the
high intensity (80%) exercise test was much shorter
than in the moderate intensity (60%) exercise test.
We also found that the variability in endurance
time as evaluated by the coefficients of variation
was less in the 80% test than in the 60% test.
Moreover, the endurance time was more sensitive
in detecting changes after administration of salbu-
tamol or ipratropium bromide during the 80% test.
Therefore, we conclude that the high intensity
endurance test will be more favorable in clinical
trials than the moderate intensity endurance test,
when using the endurance time as an outcome
measure of exercise capacity.
Endurance time has been reported to be a more
sensitive measure of exercise capacity than the
6-min walking distance or peak ’VO2 on incremental
tests in detecting changes after bronchodilator
administration,4 in pulmonary rehabilitation pro-
gram13–16 or with oxygen therapy.17 Therefore,
endurance time is used as an outcome measure of
exercise capacity, because a higher response index
allows clinical trials to be performed with fewer
candidates. Presently, however, there are no
standard protocols for sub-maximal endurance
testing. Most notably, there has been little discus-
sion regarding the most appropriate intensity of
exercise during endurance testing.
Previously, we compared different exercise per-
formance tests in evaluating the effects of oxitro-
pium bromide on exercise capacity, and found that
the endurance time when tests were performed at
80% of the Wmax was a responsive measure,
4 as was
also demonstrated in the present study. A recent
large-scale study to investigate the effects of
tiotropium bromide on exercise capacity in 187
COPD patients was performed using steady-state
cycle ergometry at 75% maximum work rate.3 Other
studies13–17 have used high intensity endurance
tests at more than 75% of the Wmax; and have
demonstrated positive effects of medical interven-
tions on endurance time. Shorter exercise endur-
ance tests performed at high intensity are
beneficial in evaluating exercise capacity in pa-
tients with COPD, because these tests are practical
to apply but also prevent the patients from
stopping exercise due to psychological reasons such
as a loss of motivation.
On the endurance test at 60% of the Wmax in the
present study, the improvements in the endurance
time after bronchodilators did not reach statisti-
cally significant differences. In addition, in the
present study, there were 6 patients who cycled
more than 20min once, although the mean endur-
ance time was around 9–10min. In another study,18
COPD subjects with a mean FEV1 of 1.68 l and 50%
predicted had no difficulty in sustaining endurance
exercise at 50% of the Wmax for 20min, although
their mean endurance time at 75% of the Wmax was
only about 6min. Although both the variability
evaluated as the coefficient of variation and the
range of differences in endurance time following
bronchodilators (Fig. 1) were greater in the 60%
test, these might have been due to the longer
exercise time.
Exercise duration time with incremental exercise
testing has been recommended to be about
10min.19,20 Franco et al.21 also selected 10min as
the total duration of sub-maximal exercise endur-
ance, because metabolic and physiologic responses
usually reach a plateau within 5–10min of exertion
at a constant work load. In addition, the duration of
exertion may influence perceptual responses.21 It is
interesting in the present study that, although the
peak physiologic exercise indices evaluated by ’VO2 ;
’VCO2 and
’VE were lower in the moderate intensity
exercise tests, as predicted based on past re-
ports,18,21 patients rated rather higher peak Borg
scores. According to Fig. 2, with moderate intensity
exercise, dyspnoea peaked at approximately 6min,
after which the monotony of exercise might have
affected the slight increase in dyspnoea. There-
fore, endurance testing lasting more than 10min at
moderate or low intensity might be less favorable
when using endurance time as an outcome.
In the present study, the endurance time after
placebo at 80% of the Wmax was strongly correlated
to that at 60% of the Wmax: However, the difference
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Figure 2 Dyspnoea evaluated by the Borg scale is shown
over time after administration of placebo during cycle
endurance tests at 80% (solid lines) and 60% (dashed
lines) of the maximum work rate in patients with COPD.
(Values are shown as mean7SEM.)
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in the endurance time between placebo and
bronchodilators at 80% was not significantly corre-
lated with that at 60%. One reason for this
observation may be that exercise limitations
differed between high and moderate intensity
endurance tests. Therefore, the effects of bronch-
odilators on the endurance time might have been
detected differentially. Although exercise limita-
tion is diverse, peripheral muscular fatigue, in
addition to ventilatory and gas-exchange limita-
tions, is considered to be a main contributor in
COPD.22,23 As an expected weakness, high intensity
exercise would put a greater load on patients’ legs,
and cycle ergometry involves strictly local leg
exercise, rather than whole body exercise,
although we did not evaluate breathlessness and
leg fatigue separately as a limitation of the present
study. On the other hand, prolonged constant
exercise at moderate intensity exercise may affect
patients psychologically due to boredom and so on.
Some limitations of the present study should be
mentioned. First, although the significant improve-
ments in the endurance time were detected on the
high intensity tests, their changes might be small in
absolute terms. How they are reflected in daily
activities of patients with COPD remains to be
investigated, although we previously examined the
relationship between the cycle endurance time,
and other measures of exercise capacity, pulmon-
ary function, dyspnoea and health-related quality
of life.24 For the sub-maximal exercise testing to be
used more as an outcome measure, the minimum
clinically important difference should be estab-
lished. Second, we did not calculate the lactic
threshold as an outcome measure in the present
study. Therefore, we cannot present any data on
how many patients exercised below their lactic
threshold although it is possible that some patients
might do so especially on the moderate intensity
tests. Such a detailed analysis should be performed
in the future. Third, the reasons for stopping
exercise might be different between the mild to
moderate and the severe COPD patients. There-
fore, separate analyses between them might have
revealed more information, although we did not do
this due to the small sample size in the present
study.
In the present study, we compared the endurance
test results between 80% and 60% of the Wmax:
When the endurance time is used as an outcome
measure of exercise capacity, we recommend that
high intensity endurance exercise is preferable to
moderate intensity exercise, because the shorter
duration of exercise is more practical, and the
results are less variable and more sensitive in
detecting changes after medical intervention.
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